Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 Entrada Therapeutics, today announced that the United States Food and …
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44Read More
25 February 2025 by Lizzie Cox
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 Entrada Therapeutics, today announced that the United States Food and …
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44Read More

14 February 2025 by Lizzie Cox
Family Science Education Day and Charity Dinner Dance Join us for a Family Day at Birmingham's Think Tank Science Museum followed by a Charity …
Family Science Education Day and Charity Dinner DanceRead More
11 February 2025 by Lizzie Cox
Action Duchenne launches Webinar Series 2025 Action Duchenne brings a great initiative to further support the Duchenne community through their …

6 February 2025 by Lizzie Cox
Action Duchenne Expands All-Through Support into Scotland PRESS RELEASE FOR IMMEDIATE RELEASE: Action Duchenne to deliver vital support to …
Action Duchenne Expands All-Through Support into ScotlandRead More

13 January 2025 by John Marrin
Action Duchenne welcomes the exciting news from the Scottish Medicines Consortium’s (SMC) positive recommendation for vamorolone for the treatment of …
SMC Recommends Vamorolone for Treating DMD in ScotlandRead More

23 December 2024 by Lizzie Cox
20 December 2024 by Mehreen Arif
Action Duchenne is pleased to share great news with the Duchenne community. Givinostat has been approved by the Medicines and Healthcare products …
MHRA approves Givinostat as a treatment for Duchenne muscular dystrophyRead More

17 December 2024 by John Marrin
Edgewise Therapeutics, announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy. …

10 December 2024 by John Marrin
Action Duchenne is excited to share the news that the National Institute for Health and Care Excellence (NICE) has issued final draft guidance …
NICE Recommends Vamorolone for Treating DMD in EnglandRead More

5 December 2024 by John Marrin
REGENXBIO, a leading clinical-stage biotechnology company focused on advancing transformative gene therapies, announced in late November that the …
REGENXBIO Announces Pivotal Phase of AFFINITY DUCHENNE Clinical Trial for RGX-202 Read More

3 December 2024 by Lizzie Cox
As we mark International Days of Persons with Disabilities today, 3rd December, we are delighted to share significant milestones in our ‘All-through …
Empowering lives on International Day of Persons with DisabilitiesRead More
15 November 2024 by John Marrin
Summary We are excited to announce that Givinostat, a new HDAC (histone deacetylase) inhibitor treatment currently under regulatory review, is now …
Givinostat Early Access Programme Launches for Duchenne Muscular Dystrophy PatientsRead More
Action Duchenne
2nd Floor
South
One Castle Park
Tower Hill
Bristol
BS2 OJA
0300 102 1762
info@actionduchenne.org
